LARISSA SPHEERIS: Open Payments
NPI 1386247526 · SUGAR LAND, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,597 in 187 payments from 22 companies in 2025. Trend: 2023 $3,535 · 2024 $4,271 · 2025 $3,597
Food & beverage: $3,597
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 38 | $604 |
| UCB, Inc. | 22 | $519 |
| PFIZER INC. | 27 | $349 |
| EMD Serono, Inc. | 13 | $305 |
| SK Life Science, Inc. | 10 | $295 |
| Neurocrine BioSciences, Inc. | 11 | $270 |
| Novartis Pharmaceuticals Corporation | 19 | $222 |
| ARGENX US, INC. | 7 | $199 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $119 |
| Eisai Inc. | 5 | $113 |
Products named: QULIPTA, NURTEC ODT, INGREZZA, KESIMPTA, Rystiggo, VYVGART HYTRULO, Fintepla, UBRELVY.
Industry payments across TX — which companies pay providers there.
